search
Back to results

Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity

Primary Purpose

Myocardial Injury

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
N-acetyl cysteine
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Myocardial Injury focused on measuring Aluminum phosphide poisonings, Intralipid emulsion, N-acetylcystiene, Myocardial injury, Echocardiography

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Presentation with symptomatic acute ALP poisoning.
  • History of exposure including reliable identification of the compound based on the container brought by patient's relatives.
  • The suggestive clinical manifestations following shortly after a single exposure to ALP.

Exclusion Criteria:

  • Co-ingestion or exposure to other substances in addition to ALP.
  • Patients had major medical conditions (e.g., cardiovascular disease, renal or hepatic failure).
  • Patients received treatment in any hospital or medical center before admission - other than emergency department of Assiut University Hospital.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    N-acetyl cysteine (NAC)

    Intra lipid emulsion (ILE)

    Arm Description

    Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.

    Conservative management + ILE infusion 10 ml/hr + normal saline infusion

    Outcomes

    Primary Outcome Measures

    Echocardiography
    Follow up cardiac function by echocardiography focusing on LV EF

    Secondary Outcome Measures

    Renal function test
    Effect on renal function by measuring serum creatinine and serum BUN
    Total days of ICU stay
    ICU stay

    Full Information

    First Posted
    March 21, 2022
    Last Updated
    May 8, 2022
    Sponsor
    Assiut University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05370729
    Brief Title
    Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity
    Official Title
    Impact of Combining N-acetylcysteine Intravenous Infusion and Intralipid Emulsion Infusion Versus Intralipid Infusion Alone on Myocardial Injury in Aluminum Phosphide Toxicity
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    May 2022 (Anticipated)
    Primary Completion Date
    May 2024 (Anticipated)
    Study Completion Date
    May 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Assiut University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Assess impact of ILE and NAC in morbidity and mortality when used as adjuvant therapy to routine management of acute ALP poisoning.
    Detailed Description
    Aluminum phosphide (ALP) is one of the solid fumigant pesticides. In Egypt, ALP is extensively used to protect grains against insects and rodents. It is available in the form of tablets known as "grain tablet". Suicidal ingestion of ALP tablets is obviously increasing in developing countries. This is attributed to its wide use, free availability in the market, and its low cost. Aluminum phosphide toxicity is extremely fatal. The conveyed mortality rate differs from 37-100%. More than 90% of patients die within the first 24 hours, mainly due to cardiac dysrhythmia. Despite continuous research, no effective antidote has been reported for this lethal poisoning so far. PH3 is phosphorus trihydride and solubility of phosphorus can affect PH3. Solubilities of phosphorus are as follows: In water: 1 part/300,000 parts water; in absolute alcohol: 1 g/400 mL. One gram phosphorus dissolves in 80 ml olive oil, 60 ml oil of turpentine, and about 100 mL of almond oil. So, PH3 might also have lipid soluble property and used IV lipid emulsion may counter its effects. Intravenous lipid emulsion (ILE) is a sterile fat emulsion prepared for intravenous administration as a source of calories and essential fatty acids. Its main components include up to 20% soybean oil, 1.2% egg yolk phospholipids, 2.25% glycerin, and water for injection. In addition, sodium hydroxide has been added to adjust the pH, so that the final pH is 8. Based on animal models and clinical studies, ILE is an established antidote for local-anesthetic drugs systemic toxicity. Besides, ILE has been well used for resuscitation of severe toxicities caused by various lipophilic non-local anesthetic drugs. N-acetylcysteine (NAC) is a well-studied compound which is commonly used in the treatment of paracetamol poisoning. It has shown to replenish cellular glutathione stores in addition to the strong antioxidant properties. NAC has shown to reduce mortality, hospitalization time, and need for mechanical ventilation in ALP poisoning. A cohort study by Agarwal reported survival benefit in patients who received treatment with NAC compared to the control group. Brain natriuretic peptide (BNP) is an excellent biomarker because it can be detected in the early stages of ischemia and decreases shortly after ischemia allowing better detection of re-injury. A metabolite of BNP, Nterminal pro-BNP, NT-proBNP, is relatively easy to measure and predicts short and long term outcomes. BNP is a 32-amino-acid peptide synthesized predominantly from the ventricular myocardium and is released in proportion to the degree of wall stress. Although it has gained recent prominence in the diagnosis and treatment of heart failure, BNP has recently shown promise in predicting the extent of myocardial ischemia in acute coronary syndromes. For instance, the magnitude of BNP released between 1 and 7 days after a myocardial infarction is predictive of left ventricular dysfunction, heart failure, and mortality.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Myocardial Injury
    Keywords
    Aluminum phosphide poisonings, Intralipid emulsion, N-acetylcystiene, Myocardial injury, Echocardiography

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    58 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    N-acetyl cysteine (NAC)
    Arm Type
    Experimental
    Arm Description
    Conservative management + ILE infusion 10 ml/hr + N-acetyl cysteine (NAC) infusion 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
    Arm Title
    Intra lipid emulsion (ILE)
    Arm Type
    No Intervention
    Arm Description
    Conservative management + ILE infusion 10 ml/hr + normal saline infusion
    Intervention Type
    Drug
    Intervention Name(s)
    N-acetyl cysteine
    Other Intervention Name(s)
    NAC
    Intervention Description
    Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
    Primary Outcome Measure Information:
    Title
    Echocardiography
    Description
    Follow up cardiac function by echocardiography focusing on LV EF
    Time Frame
    24 hours
    Secondary Outcome Measure Information:
    Title
    Renal function test
    Description
    Effect on renal function by measuring serum creatinine and serum BUN
    Time Frame
    24 hours
    Title
    Total days of ICU stay
    Description
    ICU stay
    Time Frame
    Up to two weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Presentation with symptomatic acute ALP poisoning. History of exposure including reliable identification of the compound based on the container brought by patient's relatives. The suggestive clinical manifestations following shortly after a single exposure to ALP. Exclusion Criteria: Co-ingestion or exposure to other substances in addition to ALP. Patients had major medical conditions (e.g., cardiovascular disease, renal or hepatic failure). Patients received treatment in any hospital or medical center before admission - other than emergency department of Assiut University Hospital.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Tassbeeh Kamal
    Phone
    01065656202
    Email
    tk.zanaty_92@med.aun.edu.eg
    First Name & Middle Initial & Last Name or Official Title & Degree
    Shimaa A Hassan, PHD, MD
    Phone
    01002953253
    Email
    shimaa.abbas@med.aun.edu.eg
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ola M Wahba, PHD, MD
    Organizational Affiliation
    Assiut University
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    26816450
    Citation
    Baruah U, Sahni A, Sachdeva HC. Successful management of aluminium phosphide poisoning using intravenous lipid emulsion: Report of two cases. Indian J Crit Care Med. 2015 Dec;19(12):735-8. doi: 10.4103/0972-5229.171412.
    Results Reference
    background
    PubMed Identifier
    23148565
    Citation
    Tehrani H, Halvaie Z, Shadnia S, Soltaninejad K, Abdollahi M. Protective effects of N-acetylcysteine on aluminum phosphide-induced oxidative stress in acute human poisoning. Clin Toxicol (Phila). 2013 Jan;51(1):23-8. doi: 10.3109/15563650.2012.743029. Epub 2012 Nov 14.
    Results Reference
    background
    PubMed Identifier
    25316977
    Citation
    Agarwal A, Robo R, Jain N, Gutch M, Consil S, Kumar S. Oxidative stress determined through the levels of antioxidant enzymes and the effect of N-acetylcysteine in aluminum phosphide poisoning. Indian J Crit Care Med. 2014 Oct;18(10):666-71. doi: 10.4103/0972-5229.142176.
    Results Reference
    background
    PubMed Identifier
    9244219
    Citation
    Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997 Jul 15;96(2):509-16. doi: 10.1161/01.cir.96.2.509.
    Results Reference
    background

    Learn more about this trial

    Impact of N-acetylcysteine Infusion and Intralipid Infusion on Myocardial Injury in Aluminum Phosphide Toxicity

    We'll reach out to this number within 24 hrs